These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35925211)

  • 1. [Bullous drug reaction after pembrolizumab administration: two case reports].
    Golle L; Michl C; Kreft B
    Dermatologie (Heidelb); 2022 Dec; 73(12):959-964. PubMed ID: 35925211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Harr T; French LE
    Chem Immunol Allergy; 2012; 97():149-66. PubMed ID: 22613860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Lerch M; Mainetti C; Terziroli Beretta-Piccoli B; Harr T
    Clin Rev Allergy Immunol; 2018 Feb; 54(1):147-176. PubMed ID: 29188475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma.
    Gallo Marin B; Oliva R; Kahn B; Borgovan T; Brooks BE; Massoud CM
    R I Med J (2013); 2022 Apr; 105(3):34-36. PubMed ID: 35349618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Acute life-threatening drug reactions of the skin].
    Mockenhaupt M
    Hautarzt; 2018 May; 69(5):364-375. PubMed ID: 29721625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxic epidermal necrolysis associated with pembrolizumab.
    Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A
    J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry.
    Diphoorn J; Cazzaniga S; Gamba C; Schroeder J; Citterio A; Rivolta AL; Vighi GD; Naldi L;
    Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):196-203. PubMed ID: 26687641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Severe drug-induced skin reactions. Stevens-Johnson syndrome and toxic epidermal necrolysis].
    Mockenhaupt M
    Hautarzt; 2014 May; 65(5):415-23. PubMed ID: 24820799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China.
    Yang L; Shou YH; Li F; Zhu XH; Yang YS; Xu JH
    Burns; 2020 Jun; 46(4):959-969. PubMed ID: 31898979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levamisole induced toxic epidermal necrolysis: A case report.
    Rohilla R; Jain A
    Br J Clin Pharmacol; 2021 Mar; 87(3):1574-1577. PubMed ID: 32851655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of Stevens-Johnson syndrome following combination drug use of allopurinol, carbamazepine and phenytoin in Taiwan: A case-control study.
    Syu FK; Pan HY; Chuang PC; Huang YS; Cheng CY; Cheng FJ
    J Dermatol; 2018 Sep; 45(9):1080-1087. PubMed ID: 29963717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.
    Zhang J; Zhang P; Xu QY; Zhu YT; Chen W; Ji C
    Australas J Dermatol; 2022 Feb; 63(1):e71-e74. PubMed ID: 34463968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study.
    Frey N; Bodmer M; Bircher A; Jick SS; Meier CR; Spoendlin J
    Drug Saf; 2019 Jan; 42(1):55-66. PubMed ID: 30112729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
    Roujeau JC; Kelly JP; Naldi L; Rzany B; Stern RS; Anderson T; Auquier A; Bastuji-Garin S; Correia O; Locati F
    N Engl J Med; 1995 Dec; 333(24):1600-7. PubMed ID: 7477195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab-induced Stevens-Johnson Syndrome with Severe Ocular Complications.
    Ryu S; Jun I; Kim TI; Seo KY; Kim EK
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1533-1535. PubMed ID: 33826467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction.
    Rufini S; Ciccacci C; Politi C; Giardina E; Novelli G; Borgiani P
    Pharmacogenomics; 2015 Nov; 16(17):1989-2002. PubMed ID: 26555663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Severe skin reactions due to new medications].
    Mockenhaupt M; Paulmann M
    Hautarzt; 2018 Apr; 69(4):278-289. PubMed ID: 29568997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy.
    Hwang A; Iskandar A; Dasanu CA
    J Oncol Pharm Pract; 2019 Sep; 25(6):1520-1522. PubMed ID: 30086678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.
    Halevy S; Ghislain PD; Mockenhaupt M; Fagot JP; Bouwes Bavinck JN; Sidoroff A; Naldi L; Dunant A; Viboud C; Roujeau JC;
    J Am Acad Dermatol; 2008 Jan; 58(1):25-32. PubMed ID: 17919772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report.
    Robinson S; Saleh J; Curry J; Mudaliar K
    Am J Dermatopathol; 2020 Apr; 42(4):292-296. PubMed ID: 31567395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.